Prime Capital Investment Advisors’s Inovio Pharmaceuticals INO Stock Holding History

Prime Capital Investment Advisors’s Portfolio INO Stock Details INO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$29.8K	Sell	17,126 -899	-5%	-$1.48K	﹤0.01%	1029
2025 Q4	$31.4K	Sell	18,025 -428	-2%	-$943	﹤0.01%	1007
2025 Q3	$43.2K	Sell	18,453 -1,919	-9%	-$3.67K	﹤0.01%	983
2025 Q2	$41.5K	Sell	20,372 -9,927	-33%	-$19K	﹤0.01%	932
2025 Q1	$49.4K	Sell	30,299 -991	-3%	-$1.99K	﹤0.01%	1026
2024 Q4	$57.3K	Buy	+31,290	New	+$138K	﹤0.01%	913
2024 Q3	–	Sell	-10,036	Closed	-$81.1K	–	949
2024 Q2	$81.1K	Sell	10,036 -136	-1%	-$1.43K	﹤0.01%	890
2024 Q1	$141K	Sell	10,172 -747	-7%	-$6.45K	﹤0.01%	949
2023 Q4	$66.8K	Sell	10,919 -662	-6%	-$3.27K	﹤0.01%	930
2023 Q3	$54.1K	Buy	11,581 +7,886	+213%	+$43.6K	﹤0.01%	735
2023 Q2	$19.8K	Buy	3,695 +795	+27%	+$6.41K	﹤0.01%	762
2023 Q1	$28.5K	Buy	+2,900	New	+$49.4K	﹤0.01%	544
2020 Q2	–	Sell	-109	Closed	-$10K	–	487
2020 Q1	$10K	Buy	+109	New	+$6.72K	﹤0.01%	403

Other funds holding INO

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

BCM

Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Prime Capital Investment Advisors's INO Position: Q1 2026 in Review

Prime Capital Investment Advisors reduced its Inovio Pharmaceuticals (INO) stake by 5% in Q1 2026, selling an estimated $1.48K and leaving 17,126 shares worth $29.8K. The position accounts for ﹤0.01% of the portfolio, ranked #1029.

Prime Capital Investment Advisors first reported a position in INO in Q1 2020 and has held it in 13 quarters since. The position peaked at $141K in Q1 2024. 100 funds tracked by Wall St. Rank hold INO as of Q1 2026.

Prime Capital Investment Advisors held 17,126 shares of Inovio Pharmaceuticals worth $29.8K as of Q1 2026.
Prime Capital Investment Advisors sold 899 Inovio Pharmaceuticals shares in Q1 2026, an estimated $1.48K.
Inovio Pharmaceuticals made up ﹤0.01% of Prime Capital Investment Advisors's portfolio in Q1 2026, its #1029 holding.
Prime Capital Investment Advisors first reported a position in Inovio Pharmaceuticals in Q1 2020 and has held it in 13 quarters since.
Prime Capital Investment Advisors's Inovio Pharmaceuticals position peaked at $141K in Q1 2024.
100 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q1 2026.

Based on Prime Capital Investment Advisors's 13F filing for Q1 2026, filed 8 May 2026.